PHARMACOECONOMIC OF CKD-MBD TREATMENT: LITERATURE REVIEW

In the  majority  of hemodialysis patients there are mineral and  bone disorders, of which  the  most common is secondary hyperparathyroidism. A number of new products such as paricalcitol, cinacalcet and  some phosphate-binding drugs have  been developed and introduced in clinical practice in the past decade in order to correct this life-threatening complication of chronic kidney  disease. A number of pharmacoeconomic studies have  been carried out  to determine the  cost-effectiveness of appointing certain drugs due  to increasing of the  public  expenditure in this therapy in many  countries, including Russia. In this review, we consider a brief analysis of the methods for evaluating the profitability of medicines and the results of recent studies devoted to the evaluation of the cost-effectiveness of CKD-MBD treatment.